ATARA BIOTHERAPEUTICS, INC. (ATRA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.72M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.37M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.57M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $3.20M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$4.72M | (m) | (m) | (m) | (m) | -$3.34M* | (m) | $1.34M | (m) | $1.00K |
| 2026-03-31 | Reported | (m) | -$3.37M | (m) | (m) | (m) | (m) | -$3.07M | (m) | $164.00K | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$3.57M | (m) | (m) | (m) | $0.00* | -$9.79M* | (m) | $2.92M | (m) | $28.00K |
| 2025-06-30 | Reported | (m) | $3.20M | (m) | (m) | (m) | $0.00* | -$7.32M* | (m) | $7.31M | (m) | $3.00K |
| 2025-03-31 | Reported | (m) | $38.80M | (m) | (m) | (m) | $0.00 | -$28.14M | (m) | $27.43M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$21.76M | (m) | (m) | (m) | $0.00* | -$3.99M* | (m) | $43.92M | (m) | -$17.00K |
| 2024-06-30 | Reported | (m) | -$18.23M | (m) | (m) | (m) | $29.00K* | -$10.64M* | (m) | $33.33M | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$31.25M | (m) | (m) | (m) | $127.00K | -$29.61M | (m) | $45.51M | (m) | $24.00K |
| 2023-09-30 | Reported | (m) | -$69.61M | (m) | (m) | (m) | $281.00K* | -$51.35M* | (m) | $56.89M | (m) | -$19.00K |
| 2023-06-30 | Reported | (m) | -$71.41M | (m) | (m) | (m) | $499.00K* | -$52.80M* | (m) | $56.14M | (m) | $1.00K |
| 2023-03-31 | Reported | (m) | -$75.02M | (m) | (m) | (m) | $399.00K | -$38.43M | (m) | $62.16M | (m) | $22.00K |
| 2022-09-30 | Reported | (m) | -$84.62M | (m) | (m) | (m) | $132.00K* | -$65.06M* | (m) | $70.16M | (m) | $10.00K |
| 2022-06-30 | Reported | (m) | -$32.13M | (m) | (m) | (m) | $1.42M* | -$63.96M* | (m) | $64.90M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$88.22M | (m) | (m) | (m) | $2.60M | -$84.53M | (m) | $74.96M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$84.81M | (m) | (m) | (m) | $3.86M* | -$58.98M* | (m) | $70.33M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$84.00M | (m) | (m) | (m) | $2.06M* | -$61.58M* | (m) | $68.47M | (m) | $16.00K |
| 2021-03-31 | Reported | (m) | -$78.25M | (m) | (m) | (m) | $2.20M | -$65.70M | (m) | $64.06M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$74.71M | (m) | (m) | (m) | $503.00K* | -$52.96M* | (m) | $59.88M | (m) | $6.00K |
| 2020-06-30 | Reported | (m) | -$77.95M | (m) | (m) | (m) | $2.08M* | -$56.64M* | (m) | $61.56M | (m) | $1.00K |
| 2020-03-31 | Reported | (m) | -$74.70M | (m) | (m) | (m) | $1.33M | -$67.04M | (m) | $57.66M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$72.56M | (m) | (m) | (m) | $1.49M* | -$52.15M* | (m) | $53.54M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$75.53M | (m) | (m) | (m) | $738.00K* | -$54.59M* | (m) | $52.25M | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$67.89M | (m) | (m) | (m) | $796.00K | -$70.20M | (m) | $48.67M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$60.22M | (m) | (m) | (m) | $4.50M* | -$48.10M* | (m) | $43.35M | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$52.62M | (m) | (m) | (m) | $7.45M* | -$39.43M* | (m) | $33.39M | (m) | $3.00K |
| 2018-03-31 | Reported | (m) | -$42.45M | (m) | (m) | (m) | $19.81M | -$34.82M | (m) | $28.46M | (m) | $0.00 |
| 2017-09-30 | Reported | (m) | -$31.66M | (m) | (m) | (m) | $6.19M* | -$20.23M* | (m) | $20.60M | (m) | $0.00 |
| 2017-06-30 | Reported | (m) | -$27.91M | (m) | (m) | (m) | $3.13M* | (m) | (m) | $18.30M | (m) | $0.00 |
| 2017-03-31 | Reported | (m) | -$26.16M | (m) | (m) | (m) | $1.21M | (m) | (m) | $17.54M | (m) | $2.00K |
| 2016-09-30 | Reported | (m) | -$25.94M | (m) | (m) | (m) | $386.00K* | (m) | (m) | $18.80M | (m) | $7.00K |
| 2016-06-30 | Reported | (m) | -$19.48M | (m) | (m) | (m) | $748.00K* | (m) | (m) | $12.99M | (m) | $0.00 |
| 2016-03-31 | Reported | (m) | -$17.06M | (m) | (m) | (m) | $891.00K | (m) | (m) | $11.25M | (m) | $3.00K |
| 2015-09-30 | Reported | (m) | -$12.26M | (m) | (m) | (m) | $14.00K* | (m) | (m) | $8.11M | (m) | -$11.00K |
| 2015-06-30 | Reported | (m) | -$15.11M | (m) | (m) | (m) | $0.00* | (m) | (m) | $11.51M | (m) | $0.00* |
| 2015-03-31 | Reported | (m) | -$9.31M | (m) | (m) | (m) | $5.00K | (m) | (m) | $5.77M | (m) | $2.00K |
| 2014-09-30 | Reported | (m) | -$5.95M | (m) | (m) | (m) | $5.00K* | (m) | (m) | (m) | (m) | $0.00* |
| 2014-06-30 | Reported | (m) | -$4.53M | (m) | (m) | (m) | $4.00K* | (m) | (m) | (m) | (m) | $0.00* |
| 2014-03-31 | Reported | (m) | -$7.08M | (m) | (m) | (m) | $1.00K | (m) | (m) | (m) | (m) | -$22.00K |
| 2013-09-30 | Reported | (m) | -$2.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | -$13.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $35.86M | (m) | (m) | (m) | $0.00 | -$50.94M | (m) | $37.45M | (m) | $31.00K |
| 2024-12-31 | Reported | (m) | -$83.44M | (m) | (m) | (m) | $246.00K | -$68.72M | (m) | $151.48M | (m) | -$12.00K |
| 2023-12-31 | Reported | (m) | -$276.01M | (m) | (m) | (m) | $1.22M | -$192.98M | (m) | $224.78M | (m) | $15.00K |
| 2022-12-31 | Reported | (m) | -$280.51M | (m) | (m) | (m) | $4.19M | -$270.43M | (m) | $272.53M | (m) | $12.00K |
| 2021-12-31 | Reported | (m) | -$340.46M | (m) | (m) | (m) | $10.58M | -$220.52M | (m) | $282.00M | (m) | $46.00K |
| 2020-12-31 | Reported | (m) | -$309.05M | (m) | (m) | (m) | $4.51M | -$180.76M | (m) | $244.65M | (m) | $15.00K |
| 2019-12-31 | Reported | (m) | -$295.68M | (m) | (m) | (m) | $5.73M | -$235.63M | (m) | $216.10M | (m) | $12.00K |
| 2018-12-31 | Reported | (m) | -$237.11M | (m) | (m) | (m) | $35.92M | -$179.77M | (m) | $167.46M | (m) | -$44.00K |
| 2017-12-31 | Reported | (m) | -$121.53M | (m) | (m) | (m) | $20.23M | -$87.50M | (m) | $81.21M | (m) | -$14.00K |
| 2016-12-31 | Reported | (m) | -$81.24M | (m) | (m) | (m) | $3.02M | -$60.02M | (m) | $56.51M | (m) | $10.00K |
| 2015-12-31 | Reported | (m) | -$58.45M | (m) | (m) | (m) | $290.00K | (m) | (m) | $41.62M | (m) | -$9.00K |
| 2014-12-31 | Reported | (m) | -$28.16M | (m) | (m) | (m) | $46.00K | (m) | (m) | $15.45M | (m) | -$25.00K |
| 2013-12-31 | Reported | (m) | -$8.62M | (m) | (m) | (m) | $3.00K | (m) | (m) | (m) | (m) | $170.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |